New Preclinical Data Supports Role of Talabostat in Enhancing Immune Functions and Promoting The Body's Natural Ability to Figh
April 04 2006 - 12:00PM
Business Wire
Point Therapeutics, Inc. (NASDAQ: POTP) presented today new
preclinical data in mice indicating that talabostat's effect on the
innate immune system correlated with tumor suppression and
rejection. These data were presented at the American Association of
Cancer Research Annual Meeting (AACR) in Washington D.C. and showed
a significant increase in the infiltration of tumor-fighting
neutrophils, which are part of the innate immune system. At day 60,
the neutrophil-infiltrated tumors in the mice studied were
significantly reduced by 79% (where P is less than 0.00005) in
size. Talabostat is a new form of targeted cancer therapy that in
preclinical models appears to employ a dual mechanism of action
through the inhibition of select dipeptidyl peptidases (DPPs),
which are enzymes that digest proteins found naturally in the body,
some of which can regulate tumor growth and immune responses. By
inhibiting these select DPPs, talabostat causes an increase in IL-1
beta which in turn stimulates the production of a variety of
cytokines and chemokines that promote the anti-tumor activity of
neutrophils, macrophages and T lymphocytes. "These preclinical
results add to the growing body of peer-reviewed data demonstrating
that talabostat can enhance the innate and adaptive immune systems
and improve their ability to fight tumor growth," said Dr. Barry
Jones, Senior Vice President of Research at Point Therapeutics.
Talabostat also inhibits fibroblast activation protein (FAP), a DPP
located in the tumor stroma, which is the connective tissue
supporting tumor growth. Preclinical studies have also indicated
that talabostat's inhibition of FAP can enhance anti-tumor
activity. These new data demonstrating talabostat's inhibition of
FAP in mouse tumors were presented today at AACR by researchers at
Fox Chase Cancer Center. "We are excited by the data presented at
AACR by both Point and Fox Chase. It supports our belief that
talabostat is a unique compound that can directly suppress tumor
growth through the inhibition of FAP while also causing anti-tumor
activity by enhancing the immune system. We are pleased about the
positive preclinical and clinical results we continue to obtain
with talabostat, as we further study the compound as a novel
anti-cancer agent in lung cancer, metastatic melanoma, chronic
lymphocytic leukemia and pancreatic cancer," said Don Kiepert, CEO
of Point Therapeutics. Talabostat is currently in Phase 3 trials to
evaluate its efficacy to treat non-small cell lung cancer. It is
also being evaluated in Phase 2 studies to treat chronic
lymphocytic leukemia, pancreatic cancer and metastatic melanoma.
About Point Therapeutics, Inc.: Point is a Boston-based
biopharmaceutical company developing a portfolio of dipeptidyl
peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and
as vaccine adjuvants. Point is currently studying its lead product
candidate, talabostat, in two Phase 3 trials in non-small cell lung
cancer. Point is also studying talabostat in several Phase 2
trials, including as a single-agent in metastatic melanoma, in
combination with cisplatin in metastatic melanoma, in combination
with rituximab in advanced chronic lymphocytic leukemia, and in
combination with gemcitabine in metastatic pancreatic cancer. In
addition, Point's portfolio includes two other DPP inhibitors in
preclinical development--PT-630 for type 2 diabetes, and PT-510 as
a vaccine adjuvant. Certain statements contained herein are not
strictly historical and are "forward looking" statements as defined
in the Private Securities Litigation Reform Act of 1995. This
information includes statements with respect to the company's
clinical development programs and the timing of initiation and
completion of its clinical trials. Forward-looking statements are
statements that are not historical facts, and can be identified by,
among other things, the use of forward-looking language, such as
"believes," "feels," "expects," "may," "will," "should," "seeks,"
"plans," "schedule to," "anticipates" or "intends" or the negative
of those terms, or other variations of those terms of comparable
language, or by discussions of strategy or intentions. A number of
important factors could cause actual results to differ materially
from those projected or suggested in the forward looking statement,
including the risk factors described in Point's quarterly report on
Form 10-K for the year ended December 31, 2005 and from time to
time in Point's periodic and other reports filed with the
Securities and Exchange Commission.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Point Therapeutics (MM) (NASDAQ): 0 recent articles
More Point Therapeutics, Inc. News Articles